I can see your point Vivo , but not so sure about Merck having IMM over a barrel.Other big pharma such as Novartis,GSK and BMS may well see some value in acquiring Immutep.Not so sure Merck would be willing to take a gamble on a combo ,that’s safe ,cost effective,doubles efficiacy and also doubles if not triples total addressable market .Buy waiting within reason ,they may well give more traction to Immutep and other potential suitors,just my thoughts.For mine the clock is ticking for both Immutep and Merck
I can see your point Vivo , but not so sure about Merck having...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
43.5¢ |
Change
-0.010(2.25%) |
Mkt cap ! $517.1M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 45.0¢ | 43.0¢ | $618.8K | 1.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 21064 | 43.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.0¢ | 1500 | 1 |
View Market Depth
| Last trade - 16.10pm 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
44.0¢ |
Change
-0.010 ( 2.68 %) |
||||
| Open | High | Low | Volume | ||
| 44.0¢ | 45.0¢ | 43.0¢ | 344370 | ||
| Last updated 15.59pm 16/05/2024 ? | |||||
| IMM (ASX) Chart |